Burning Rock Biotech's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 138.79.
Burning Rock Biotech's Days Inventory for the
three
months ended in Mar. 2026 was 154.28.
Burning Rock Biotech's Days Payable for the
three
months ended in Mar. 2026 was 87.5.
Therefore, Burning Rock Biotech's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 205.57.
Burning Rock Biotech (FRA:6BU0) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Burning Rock Biotech Cash Conversion Cycle Related Terms
Burning Rock Biotech Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Burning Rock Biotech's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6BU0 vs XGN, IDXG, PRPO: Cash Conversion Cycle Comparison
For the Diagnostics & Research subindustry, Burning Rock Biotech's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Burning Rock Biotech Cash Conversion Cycle vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Burning Rock Biotech's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Burning Rock Biotech's Cash Conversion Cycle falls into.
Burning Rock Biotech Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Burning Rock Biotech's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Burning Rock Biotech (FRA:6BU0) has a Cash Conversion Cycle of 205.57 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Burning Rock Biotech and its competitors.
Is Burning Rock Biotech's Cash Conversion Cycle too high?
Burning Rock Biotech's current Cash Conversion Cycle is 205.57. The Medical Diagnostics & Research industry median Cash Conversion Cycle is 73.46. Burning Rock Biotech's value of 205.57 is 179.9% above this industry median. Overall, Burning Rock Biotech has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Burning Rock Biotech's Cash Conversion Cycle compare to XGN and IDXG?
Burning Rock Biotech's Cash Conversion Cycle of 205.57 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Cash Conversion Cycle is 73.46. Burning Rock Biotech's value of 205.57 is 179.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Diagnostics & Research company?
The median Cash Conversion Cycle among Medical Diagnostics & Research companies is 73.46, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Burning Rock Biotech's current Cash Conversion Cycle of 205.57 is 179.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Burning Rock Biotech and its competitors. For the Medical Diagnostics & Research industry, the median Cash Conversion Cycle is 73.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Burning Rock Biotech's current Cash Conversion Cycle is 205.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Burning Rock Biotech stock overvalued right now?
Based on GuruFocus' analysis, Burning Rock Biotech (FRA:6BU0) is currently considered Significantly Overvalued. The stock's GF Value™ is €6.12, compared to a current price of €8.70 — trading 42.2% above its estimated fair value. The current Cash Conversion Cycle is 205.57 and 179.9% above the Medical Diagnostics & Research industry median of 73.46. Burning Rock Biotech's overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Burning Rock Biotech (FRA:6BU0), the current Cash Conversion Cycle is 205.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Burning Rock Biotech (FRA:6BU0) Overvalued in 2026?
Based on GuruFocus' analysis, Burning Rock Biotech stock appears to be overvalued.
The current stock price of €8.70 is trading 42.2% above its estimated GF Value™ of €6.12.
GuruFocus considers Burning Rock Biotech to be Significantly Overvalued.
Key valuation signals for FRA:6BU0:
Cash Conversion Cycle: 205.57
GF Value™: €6.12 vs. price of €8.70 (42.2% above fair value)
Industry Position: 179.9% above the Medical Diagnostics & Research median
No single metric tells the full story. See the FRA:6BU0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
58GF Score
Get the complete analysis for FRA:6BU0
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6BU0 has been successfully added to your 
